Axsome Therapeutics (AXSM) had the highest return in 2019 by a mid-cap US stock, returning 3,578.3%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Axsome Therapeutics (AXSM) | 2019 | 3,578.29% |
Enphase Energy (ENPH) | 2019 | 464.36% |
Arrowhead Pharmaceuticals (ARWR) | 2019 | 421.63% |
Sibanye Gold Ltd ADR (SBSW) | 2019 | 243.6% |
Immunitybio (IBRX) | 2019 | 238.39% |
Iovance Biotherapeutics (IOVA) | 2019 | 215.62% |
Intracellular Th (ITCI) | 2019 | 208.54% |
Eldorado Gold (EGO) | 2019 | 179.79% |
Lattice Semiconductor (LSCC) | 2019 | 179.01% |
TG Therapeutics (TGTX) | 2019 | 174.75% |
Palomar (PLMR) | 2019 | 172.92% |
Boot Barn (BOOT) | 2019 | 172.52% |
Krystal Biotech (KRYS) | 2019 | 171.2% |
ACADIA Pharmaceuticals (ACAD) | 2019 | 170.08% |
Vipshop (VIPS) | 2019 | 166.35% |
Novocure (NVCR) | 2019 | 159.29% |
Plug Power (PLUG) | 2019 | 154.84% |
Cirrus Logic (CRUS) | 2019 | 153.18% |
Frontline (FRO) | 2019 | 137.6% |
Apellis Pharmaceuticals (APLS) | 2019 | 137.18% |
YETI (YETI) | 2019 | 136.12% |
Scorpio Tankers (STNG) | 2019 | 135.18% |
NeoGenomics (NEO) | 2019 | 134.19% |
Sonic Automotive (SAH) | 2019 | 132.79% |
GDS (GDS) | 2019 | 129.76% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
